- Eli Lilly (NYSE:LLY) and Boehringer Ingelheim reports results from EMPA-REG OUTCOME trial assessing Jardiance and placebo, both added to standard of care in adults with type 2 diabetes and established cardiovascular disease.
- Total cardiovascular events included 3P-MACE (a composite of non-fatal heart attack, non-fatal stroke and cardiovascular death), hospitalization for heart failure and all-cause hospitalization.
- Previously, Jardiance reduced the relative risk of 3P-MACE by 14%, driven by a 38% reduction in the relative risk of cardiovascular death.
- These new exploratory analyses show that, when added to standard of care, Jardiance reduced the relative risk of the following total (first plus recurrent) events versus placebo:
- 3P-MACE by 22%
- Hospitalizations for heart failure by 42%
- All-cause hospitalizations by 17%
- Fatal or non-fatal myocardial infarction (heart attack) by 21%
- Coronary heart disease events (a composite of myocardial infarction and coronary revascularization) by 20%.
- The findings were published in The Lancet Diabetes & Endocrinology.
- The overall safety profile of Jardiance was consistent with that of previous trials.
- Jardiance is a prescription medicine used along with diet and exercise to lower blood sugar and reduce the risk of cardiovascular death in adults with type 2 diabetes.